Results 41 to 50 of about 19,263 (243)

Determining therapeutic susceptibility in multiple myeloma by single-cell mass accumulation [PDF]

, 2017
Multiple myeloma (MM) has benefited from significant advancements in treatment that have improved outcomes and reduced morbidity. However, the disease remains incurable and is characterized by high rates of drug resistance and relapse.
Calistri, Nicholas L, Cetin, Arif Engin, Kimmerling, Robert John, Manalis, Scott R, Olcum, Selim A., Stevens, Mark M.   +5 more
core   +1 more source

Preclinical characterization of ISB 1342, a CD38 × CD3 T-cell engager for relapsed/refractory multiple myeloma [PDF]

, 2023
Although treatment of multiple myeloma (MM) with daratumumab significantly extends the patient's lifespan, resistance to therapy is inevitable. ISB 1342 was designed to target MM cells from patients with relapsed/refractory MM (r/r MM) displaying lower ...
Berret, Jérémy, Blein, Stanislas, Borthakur, Gautam, Carretero-Iglesia, Laura, Chimen, Myriam, Doucey, Marie-Agnès, Drake, Adam, Edwards, Claire, Edwards, James, Estoppey, Carole, Gudi, Girish S, Kaya, Zeynep, Kervoëlen, Charlotte, Laurendon, Amélie, Macoin, Julie, Maiti, Abhishek, Matthes, Thomas, Mbow, M Lamine, Menon, Vinu, Menoret, Emmanuelle, Monney, Thierry, Moreau, Philippe, Nallet, Emilie, Pais Ferreira, Daniela, Pellat-Deceunynck, Catherine, Perro, Mario, Pihlgren, Maria, Pouleau, Blandine, Srivastava, Ankita, Suere, Perrine, Udupa, Venkatesha, Zhukovsky, Eugene   +31 more
core   +2 more sources

Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab

Haematologica, 2011
Background In our efforts to develop novel effective treatment regimens for multiple myeloma we evaluated the potential benefits of combining the immunomodulatory drug lenalidomide with daratumumab.
Michael. S. van der Veer, Michel de Weers, Berris van Kessel, Joost M. Bakker, Shulamiet Wittebol, Paul W.H.I. Parren, Henk M. Lokhorst, Tuna Mutis   +7 more
doaj   +1 more source

ARQ-197, a small-molecule inhibitor of c-Met, reduces tumour burden and prevents myeloma-induced bone disease in vivo [PDF]

, 2018
The receptor tyrosine kinase c-Met, its ligand HGF, and components of the downstream signalling pathway, have all been implicated in the pathogenesis of myeloma, both as modulators of plasma cell proliferation and as agents driving osteoclast ...
Buckle, C.H., Chantry, A.D., Down, J.M., Evans, H.R., Fisher, M., Lath, D.L., Lawson, M.A.   +6 more
core   +2 more sources

Plant‐Produced Viral Nanoparticles Decorated with Nanobodies Against HER2 Improve Retention and Recruitment of Immune Cells in Solid Tumors

Advanced Healthcare Materials, EarlyView.
Potato virus X is a filamentous RNA plant virus that can be engineered into a molecular tool for cancer therapy. We produced genetically‐encoded virus‐derived nanoparticles decorated with nanobodies targeting cancer cell receptors, epidermal growth factor receptor (EGFR) and human epidermal growth factor 2 (HER2).
Enrique Lozano‐Sanchez, Miguel A. Moreno‐Gonzalez, Fernando Merwaiss, Nicole F. Steinmetz, José‐Antonio Daròs   +4 more
wiley   +1 more source

Daratumumab in untreated newly diagnosed multiple myeloma

Therapeutic Advances in Hematology, 2019
The treatment of multiple myeloma has evolved markedly in the last decade, but mortality remains high, emphasizing the need for more effective therapies.
Nadine Abdallah, Shaji K. Kumar
doaj   +1 more source

T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities

Advanced Science, EarlyView.
T cell exhaustion limits immunotherapy efficacy. This article delineates its progression from stem‐like to terminally exhausted states, governed by persistent antigen, transcription factors, epigenetics, and metabolism. It maps the exhaustion landscape in the TME and proposes integrated reversal strategies, providing a translational roadmap to overcome
Yang Yu, Xiaoyu Yao, Qingyang Wang, Mengrui Yang, Runze Li, Jiangjiang Qin, Jing Zhuang, Changgang Sun   +7 more
wiley   +1 more source

Case report: Daratumumab for treatment of refractory late or chronic active antibody-mediated rejection in renal allograft recipients with high levels of de novo donor-specific antibodies

Frontiers in Immunology, 2023
BackgroundLate or chronic active antibody-mediated rejection (AMR) associated with de novo donor-specific antibodies (dnDSA) after renal transplantation is a great clinical challenge because it is often resistant to conventional therapies.
Lan Zhu, Lan Zhu, Lan Zhu, Lan Zhu, Zhiliang Guo, Daqiang Zhao, Daqiang Zhao, Daqiang Zhao, Daqiang Zhao, Rula Sa, Guangyuan Zhao, Guangyuan Zhao, Guangyuan Zhao, Guangyuan Zhao, Hui Guo, Hui Guo, Hui Guo, Hui Guo, Gang Chen, Gang Chen, Gang Chen, Gang Chen   +21 more
doaj   +1 more source

Clinical applications of personalized medicine: a new paradigm and challenge [PDF]

, 2017
The personalized medicine is an emergent and rapidly developing method of clinical practice that uses new technologies to provide decisions in regard to the prediction, prevention, diagnosis and treatment of disease.
Borro, Marina, DI SANZO, Mariantonia, Fineschi, Vittorio, Frati, Paola, LA RUSSA, Raffaele, Santurro, Alessandro, Scopetti, Matteo, Simmaco, Maurizio   +7 more
core   +1 more source

Navigating the Post‐BCMA/GPRC5D Landscape: Efficacy of Selinexor, Bortezomib, and Dexamethasone After Sequential Immunotherapy Failure in Penta‐Refractory Multiple Myeloma—A Multicenter Analysis

American Journal of Hematology, EarlyView.
ABSTRACT Patients with relapsed/refractory multiple myeloma (RRMM) who are penta‐drug refractory, defined as resistant to two proteasome inhibitors, two immunomodulatory agents, and an anti‐CD38 monoclonal antibody, face a dismal prognosis, particularly after exposure to T‐cell–redirecting therapies.
Maximilian Al‐Bazaz, Winfried Alsdorf, Lisa Leypoldt, Piet Sonnemann, Christoph Schaefers, Jule Artzenroth, Marie Harzer, Abdulaziz Kamili, Leandra Bartke, Leon Cords, Jan Vorwerk, Theo Leitner, Markus Maulhardt, Kerstin Brinkert, Annamaria Brioli, Tim Richardson, Udo Holtick, Stefan M. Hillmann, Hans Salwender, Cyrus Khandanpour, Carsten Bokemeyer, Katja Weisel, Ricardo Kosch   +22 more
wiley   +1 more source